DDInter1042 DDInter842
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Insulin glargine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Grepafloxacin may lead to a major life threatening interaction when taken with Encorafenib
Grepafloxacin may lead to a major life threatening interaction when taken with Insulin glargine